Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>IMS</strong> COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING<br />
Lead ing Dose Forms:<br />
liq uids 28%<br />
gels/sols 24%<br />
pow ders/gran ules 17%<br />
cap sules 10%<br />
creams 7%<br />
SANDOZ<br />
Full Name: Sandoz d.d., Rep re sen ta tive Of fice<br />
Street Ad dress: Ruzinovska 42, 821 03<br />
Bratislava<br />
Tel: +421 2 4820 0600<br />
Fax: +421 2 4820 0650<br />
Home Page: www.sandoz.sk<br />
De scrip tion: Im porter, pro moter, sales/detailer.<br />
Pro motes, sells/de tails for other com pa nies. Prod -<br />
uct ranges in clude: phar ma ceu ti cal prod ucts<br />
(branded, pre scrip tion), hos pi tal<br />
pharmaceuticals, bio tech nol ogy prod ucts, herbal<br />
products.<br />
Con tacts (Pharm): Chair man: Chris tian Wieser;<br />
Gen eral Con tact: Chris tian Wieser<br />
Sub sid iary of: Lek, Slovenia<br />
Phar ma ceu ti cal Sales: US$ 28-30 mil lion<br />
Prod ucts (% of Sales by Lead ing 5): 35-40%<br />
Ther a peu tic Classes (% of Sales by Lead ing<br />
5): 60-65%<br />
Dose Forms (% of Sales by Lead ing 5):<br />
85-90%<br />
Prin ci pal Prod ucts:<br />
AMOKSIKLAV (pen i cil lin broad spec trum)<br />
TU LIP (cho les terol/triglyceride reg u lat ing prep a -<br />
ra tion)<br />
AMLOPIN (cal cium an tag o nist plain)<br />
EDICIN (an ti bac te rial other)<br />
GINGIUM (ce re bral/pe riph eral vasotherapeutic)<br />
Ther a peu tic Range:<br />
antibacterials sys temic 35%<br />
lipid-reg u lat ing/antiatheroma prep a ra tions<br />
11%<br />
cal cium an tag o nists 6%<br />
urologicals 5%<br />
ant ac ids/antiflatulents/antiulcerants 4%<br />
Lead ing Dose Forms:<br />
coated tab lets 34%<br />
tab lets 28%<br />
vi als 10%<br />
cap sules 9%<br />
liq uids 6%<br />
SLOVENIA<br />
LEK<br />
Full Name: Lek Pharmaceuticals d.d.<br />
Street Ad dress: 1526 Ljubljana, Verovskova 57<br />
Tel: +386 1 580 2111<br />
Fax: +386 1 568 3517<br />
Email: info@lek.si<br />
Home Page: www.lek.si/eng<br />
De scrip tion: Re searcher, de vel oper, man u fac -<br />
turer, im porter, ex porter, dis trib u tor, pro moter.<br />
Man u fac tures, dis trib utes for other com pa nies.<br />
Prod uct ranges in clude: phar ma ceu ti cal prod ucts<br />
(branded, unbranded, pre scrip tion, non-pre scrip -<br />
tion), hos pi tal pharmaceuticals, fine chem i cals,<br />
in ter me di ates, raw ma te ri als, di ag nos tic prod -<br />
ucts, vet er i nary pharmaceuticals. Es tab lished<br />
1946. Di vi sions in clude: Pharmaceuticals; Ac tive<br />
Phar ma ceu ti cal Ingredients; OTC; Animal Health;<br />
Cosmetics; Medical.<br />
Con tacts (Pharm): Chair man: Janja Bratos;<br />
Man u fac ture: Bojan Dolenc; Mar ket Re search:<br />
Bojan Videtic; Gen eral Con tact: Ales Koce<br />
Par ent of: Lek, Mac e do nia; Pharmatech, Ro ma -<br />
nia (100%); Sandoz, Slo vak Re pub lic;<br />
Sanofi-Synthelabo Lek, Slovenia (49%).<br />
Sub sid iary of: Novartis, Swit zer land (100%)<br />
Phar ma ceu ti cal Sales: US$ 55-60 mil lion<br />
Prod ucts (% of Sales by Lead ing 5): 35-40%<br />
Ther a peu tic Classes (% of Sales by Lead ing<br />
5): 60-65%<br />
Dose Forms (% of Sales by Lead ing 5):<br />
85-90%<br />
Prin ci pal Prod ucts:<br />
TU LIP (cho les terol/triglyceride reg u lat ing prep a -<br />
ra tion)<br />
LEKADOL (an al ge sic non-nar cotic)<br />
OLIVIN (ACE in hib i tor plain)<br />
ORTANOL (antiulcerant)<br />
AMOKSIKLAV 2 (pen i cil lin broad spec trum)<br />
Ther a peu tic Range:<br />
antibacterials sys temic 17%<br />
lipid-reg u lat ing/antiatheroma prep a ra tions<br />
12%<br />
an al ge sics 12%<br />
ant ac ids/antiflatulents/antiulcerants 11%<br />
renin-an gio ten sin sys tem agents 9%<br />
Lead ing Dose Forms:<br />
tab lets 46%<br />
coated tab lets 18%<br />
cap sules 11%<br />
am poules 6%<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 205
Change language